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Abstract: Citrate, generated in the mitochondria, is a key metabolite that might link metabolism 
with signaling, chromatin structure and transcription to orchestrate mesenchymal stem cells (MSCs) 
fate determination. Based on a detailed morphological analysis of 3D reconstruction of 
mitochondria and nuclei in single cells, we identified contact sites between these organelles that 
drastically increase in volume and number during the early stage of mesenchymal stem cell 
differentiation. These contact sites create a microdomain that facilitates exchange of signals from 
mitochondria to the nucleus. Interestingly, we found that the citrate derived from mitochondria is 
necessary for osteogenic lineage determination. Indeed, inhibition of the citrate transporter system 
dramatically affected osteogenesis, reduced citrate levels that could be converted in α-ketoglutarate, 
and consequently affected epigenetic marker H3K9me3 associated with the osteogenesis 
differentiation process. These findings highlight that mitochondrial metabolites play key regulatory 
roles in the MSCs differentiation process. Further in-depth investigation is needed to provide novel 
therapeutic strategies in the field of regenerative medicine. 
Keywords: osteogenesis; citrate; α-ketoglutarate; mitochondrial metabolism; mesenchymal stem 
cells; mitochondria-nucleus communication 
 
1. Introduction 
Mesenchymal stem cells (MSCs) are multipotent cells that give rise to osteoblasts, adipocytes, 
and chondrocytes [1–3], whereby the studying of their differentiation processes is of great interest for 
their promising application in tissue engineering of mesenchymal tissues.  
MSC nuclear reprogramming during differentiation processes has been widely characterized [4], 
but several recent studies have focused on the novel mechanisms involving mitochondrial activities 
in stem cell biology. 
Variations in the abundances, morphology, and functions of mitochondria in different stem cell 
types have been described [3,5–9], and it has been established that upregulation of mitochondrial 
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biogenesis and metabolic shifts toward oxidative phosphorylation are hallmarks of differentiation in 
MSCs [10,11]. In particular, osteogenesis is followed by the development of cristae, with increased 
levels of proteins involved in mitochondrial biogenesis as well as enzymes of the tricarboxylic acid 
(TCA) cycle and subunits of respiratory chain complexes. Consequently, the oxygen consumption 
rate, the mitochondrial membrane potential, and the intracellular ATP content also increase, 
indicating enhanced oxidative metabolism in mitochondria during MSC differentiation [11,12]. 
In addition to a well-established role in cellular energy metabolism, mitochondria are critical 
mediators of cell signaling [13]; however, little is known regarding the direct effect of metabolic 
pathway activity on chromatin dynamics and MSC differentiation. Extensive epigenetic remodeling 
is necessary for the differentiation of MSCs, including covalent histone or DNA modification by 
methylation, acetylation, and glycosylation to regulate transcription. Moreover, recent evidence 
suggests that metabolic intermediates of cellular metabolism are required as cofactors for epigenetic 
modulators, providing a direct link between mitochondrial metabolism and gene expression [14]. 
In this study, we identified citrate and its derivative α-ketoglutarate (αKG) as pivotal 
mitochondrial metabolites that play a specific role in stem cell fate determination toward the 
osteogenic lineage. 
2. Materials and Methods 
2.1. Cell Culture 
MSCs were extracted from human adipose tissues of healthy female patients undergoing 
cosmetic surgery procedures following guidelines from the Clinic of Plastic Surgery, University of 
Padova. Adipose tissues were digested with 0.075% collagenase type II from Clostridium hystoliticum 
(Sigma–Aldrich, St Louis, MO, USA) in phosphate-buffered saline (PBS). Floating adipocytes were 
discarded, and cells from the stromal-vascular fraction were pelleted, rinsed with medium, and 
centrifuged. MSCs were obtained after a red blood cell lysis step in NH4Cl for 10 min at room 
temperature. 
2.2. Flow Cytometry 
After dissociation by trypsin, cells were suspended in flow cytometry staining buffer (R&D 
Systems, Minneapolis, MN, USA) at a final cell concentration of 1 × 106 cells/mL. After 30 min of 
incubation with mouse anti-human CD14 R-PE, CD34 FITC, CD44 FITC, CD45 APC, CD73 APC, 
CD90 R-PE, CD105 PE-Cy 7, and HLA-DR FITC (all purchased from eBioscience TM, Thermo Fisher 
Scientific, Waltham, MA, USA), cells were washed twice with 2 mL of flow cytometry staining buffer. 
The labeled cells were suspended in 500 µL of flow cytometry staining buffer, and analyzed on 
Attune NxT flow cytometer (Thermo Fisher Scientific).  
2.3. In Vitro Differentiation Protocol 
MSCs isolated from human adipose tissues were grown in Dulbecco's Modified Eagle's medium 
(DMEM)-low-glucose (LG) (EuroClone S.p.A., Milan, Italy) supplemented with 10% fetal bovine 
serum, 2 mM L-glutamine, and antibiotics (penicillin 100 µg/mL and streptomycin 10 µg/mL) at 37 
°C in a humidified atmosphere of 5% CO2. 
For adipogenic differentiation, DMEM-LG was replaced with DMEM-high-glucose (HG) 
(EuroClone S.p.A) plus 10 µg/mL insulin, 0.5 mM IBMX, 0.1 mM indomethacin, and 1 µM 
dexamethasone for 3, 7, and 21 days. For osteogenic differentiation, LG was replaced with DMEM-
HG plus 10 nM dexamethasone, 10 ng/mL FGF-β, and 10 mM β-glycerophosphate for 3, 7, and 21 
days. All growth factors were purchased from Sigma-Aldrich. 
2.4. Immunofluorescence Microscopy 
Immunofluorescence microscopy was performed according to standard procedures. Briefly, 
cells were fixed in 4% PFA for 20 min at room temperature, washed three times with PBS and 
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permeabilized with 0.1% Triton X-100 for 5 min at room temperature. Thereafter, unspecific binding 
sites were blocked by incubating cells in PBS supplemented with 2% bovine serum albumin (BSA, 
used as blocking buffer) for 1 h at room temperature. Cells were then incubated overnight at 4°C with 
primary antibodies and then revealed using appropriate AlexaFluor 488® or AlexaFluor 594® 
conjugates (Thermo Fischer Scientific). The nucleus was stained by Hoechst. Images were acquired 
using an LSM 510 confocal microscope (Carl Zeiss Microscopy, LLC, Jena, Germany) with a Plan-
Apochromat 63x/1.4 oil objective (Carl Zeiss Microscopy, LLC). 
2.5. Measurement of Mitochondrial Number, Volume, and Identification of Mitochondrion-Nucleus Contact 
Sites 
After differentiation, cells were fixed on a glass coverslip; nuclei were stained with Hoechst and 
mitochondria with an anti-TOM20 antibody (Ab). After Z-stack acquisition, images were 
deconvoluted using Huygens Essential software (Scientific Volume Imaging B.V., Hilversum, The 
Netherlands), and a 3D reconstruction of the mitochondrial network and nucleus in a single cell was 
created using Imaris 7 (Bitplan, Zurich, Switzerland) software.  
The mitochondrial number and volume were measured for single cell. The TOM20 channel was 
used to create the 3D mitochondrial isosurface by Imaris 7, and the total volume and number of 
objects were analyzed for each of these isosurfaces. 
The colocalization between TOM20 and Hoechst, the two fluorescent signals were analyzed by 
the Imaris colocalization tool, and a colocalization channel was created. Finally, two isosurfaces 
(mitochondria and colocalization channel) were generated, and the total volume and number of 
objects were analyzed for each of these isosurfaces. 
2.6. Antibodies 
The following primary antibodies were used for immunoblotting: rabbit anti-GAPDH [2118] 
(1:5000) from Cell Signaling; rabbit anti-TOM20 [sc-11415] (1:1000) and mouse anti-HSP60 [sc-13115] 
(1:1000) from Santa Cruz Biotechnology (Dallas, TX, USA); anti-VDAC [ab-15895] (1:1000) from 
Abcam (Cambridge, UK); anti-TIM23 [611222] (1:1000) from BD Bioscience (San Jose, CA, USA). The 
following primary antibodies were used for immunofluorescence images: TOM20 [sc-11415] (1:100) 
from Santa Cruz Biotechnology, H3 [14269] (1:100), H3K9ac [9649] (1:100), and H3K9me3 [13969] 
(1:100) from Cell Signaling (Danvers, MA, USA). 
2.7. XF Bioenergetic Analysis 
Oxygen-consumption rates were measured using the SeahorseXF96 instrument according to the 
manufacturer's protocols. After differentiation, MSCs were seeded in a poly-lysine-coated XF96 
microplate at a density of 50,000 cells per well in 175 µL unbuffered XF assay medium (pH 7.4) 
supplemented with 5.5 mM glucose, 1 mM sodium pyruvate, and 1 mM glutamine for 60 minutes in 
a 37 °C non-CO2 incubator; sensor cartridges were calibrated prior to the start of assays. Respiration 
was measured in four blocks of three for 3 min. The first block measured the basal respiration rate. 
Next, 1 µM oligomycin was added to inhibit complex V (second block); 1 µM carbonylcyanide 4-
(trifluoromethoxy)-phenylhydrazone (FCCP) was added to uncouple respiration (third block). 
Finally, 2 µM antimycin A and 2 mM rotenone were added to inhibit complex III (fourth block). All 
reagents were from Agilent Technologies, Seahorse Biosciences (Santa Clara, CA). Immediately after 
finishing the measurements, cells were washed with PBS, fixed with 4% paraformaldehyde (PFA), 
and stained with 0.1% crystal violet (1 mol/L acetic acid); absorbance at 595 nm was measured as an 
index of the number of cells. 
2.8. Oil Red O Staining 
Oil red O (Sigma-Aldrich) staining of cytoplasmic droplets of neutral lipids was performed 
according to a standard procedure. Monolayer cultures were fixed in 10% neutral-buffered formalin 
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for 10 min. Oil Red O working solution was added to wells for 10 min at room temperature. After 
washing, stained cells were assessed by light microscopy. 
2.9. Alizarin Red Staining 
For Alizarin Red S (ARS) staining, cells were fixed with 10% neutral-buffered formalin for 10 
min and stained with 40 mM Alizarin Red S solution (pH 4.2) at room temperature for 10 min. After 
washing, the stained cells were examined by light microscopy. 
2.10. RNA Extraction and Quantitative Reverse Transcription Polymerase Chain Reaction (RT-PCR) 
Total RNA was extracted with TRIzol Reagent (Invitrogen, Carlsbad, CA, USA). RNA was 
purified with RNeasy Mini Kit (QiagenGmbH, Hilden, Germany), and DNase digestion was 
performed with RNase-Free DNase Set (Qiagen). The RNA quality and concentration were measured 
using a NanoDrop TM ND-1000 (Thermo Scientific). For first-strand cDNA synthesis, 1000 ng of total 
RNA from each sample was reverse-transcribed with M-MLV Reverse Transcriptase (Invitrogen/ 
Thermo Fisher Scientific, Waltham, MA, USA) following the manufacturer's protocol. 
Real-time PCR was carried out using primers designed for human genes at a concentration of 
300 nM and with FastStart SYBR GreenMaster (Roche Diagnostics, Mannheim, Germany) and a 
Rotor-Gene 3000 (Corbett Research, Sydney, Australia). The thermal cycling conditions were as 
follows: 10-min denaturation at 95 °C, followed by 40 cycles of denaturation for 10 s at 95 °C, 
annealing for 20 s at 60 °C, and elongation for 30 s at 72 °C. Data analysis was performed using the 
2ΔΔCt method: values were normalized to expression of the Transferrin Receptor (TFRC) internal 
reference, and results are reported as the fold change of target genes in the test group with respect to 
the control. 
2.11. Cell Growth Assay 
After 21 days of treatment, cells were washed with PBS, fixed in 4% PFA, and stained with 0.1% 
crystal violet. Crystal violet was dissolved with 1 mol/L acetic acid, and absorbance at 595 nm was 
measured. 
2.12. Statistical Analysis 
Results are expressed as the mean ± SD. The probability of significant differences between 
experimental groups was determined by analysis of variance (ANOVA), and results from treatments 
showing significant overall changes were subjected to post-hoc Bonferroni tests. Student’s t-test was 
employed to determine statistical significance between two groups. p values < 0.05 were considered 
statistically significant. Different labels indicate *p < 0.05, **p < 0.001, ***p < 0.0001, and ****p< 0.00001. 
3. Results 
3.1. Mitochondrion-Nucleus Contact Sites Increase Following Differentiation Processes and Mitochondrial 
Modification 
Stem cell fate regulation is principally characterized by marked nuclear reprogramming, yet the 
important dynamic rearrangement of mitochondria during differentiation suggests their direct 
involvement in these finely tuned processes. 
To investigate the role of mitochondria in MSCs, cells were isolated from human adipose tissues 
and characterized for surface markers (Supplementary Figure S1) as previously described [15,16]. 
Adipose-derived MSCs were then differentiated into adipogenic (AD) and osteogenic (OS) lineages 
for 21 days. 
Mitochondria were stained by Ab-TOM20 and nuclei by Hoechst, and the colocalization channel 
between the two signals was used to identify sites of contact between the two organelles in a single 
cell. Using 3D reconstruction of mitochondria and the colocalization channel, we showed that the 
mitochondrial total volume and number, as well as the volume and number of mitochondrion-
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nucleus contacts, increased dramatically after 7 days of adipogenic and osteogenic differentiation 
(Figure 1a,b). 
 
Figure 1. Mitochondria-nucleus contacts. Mesenchymal stem cells (MSCs) were cultured in low-
glucose (LG), adipogenic (AD) and osteogenic (OS) media for 3, 7, and 21 days, as indicated. (a) 
Representative 3D images of mitochondrial morphology, as detected by anti-TOM20 Ab 
immunofluorescence, and contact sites identified by creating the isosurface of the colocalization 
channel between nuclear staining (Hoechst) and TOM20. Magnification 40x. Scale bar 10 µm (in zoom 
panel, scale bar 5 µm). (b) Quantification of mitochondrial total volume, number, and total volume 
and number of contacts. Data are derived from ≥45 acquired cells/condition from ≥3 independent 
experiments. Data are shown as the mean ± SD. ANOVA, * p < 0.1, ** p < 0.01, *** p < 0.001, **** p < 
0.0001 with respect to the LG condition at the same time point. 
In addition, alterations in mitochondrial content and physiology were analyzed via detection of 
mitochondrial markers by immunoblotting and using a Seahorse Extracellular Flux Analyzer 
(Agilent), which measures the mitochondrial oxygen consumption rate (OCR) and the extracellular 
acidification rate (ECAR), key metrics of mitochondrial function. Our data revealed that adipogenesis 
is characterized by a progressive increase in mitochondrial mass, as shown by increase in levels of 
mitochondrial proteins such as HSP60, TOM20, VDAC, and TIM23 (Figure 2a,b). In addition, analysis 
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of the OCR/ECAR phenogram confirmed that differentiation processes are characterized by an 
essential metabolic switch. Indeed, differentiating MSCs switched from glycolytic to oxidative 
metabolism, as demonstrated by a reduction in ECAR (Figure 2c,d). In contrast to osteogenesis, two 
conditions were identified: after 7 days, mitochondrial mass increased drastically, particularly due to 
the consistent increase in the number of mitochondria; after 21 days of differentiation, mitochondrial 
mass decreased significantly (Figures 1a,b and 2a,b), as also reflected in the metabolic phenogram 
(Figure 2c–e). 
 
Figure 2. Mitochondria in MSC differentiation processes. (a) Representative immunoblot and (b) 
quantification of HSP60, TOM20, VDAC, and TIM23 protein levels normalized to GAPDH levels. (c) 
XF phenograms representing the metabolic switching of MSCs during differentiation, as detected 
using an Extracellular Flux Analyzer (Seahorse Bioscience). (d,e) Oxygen consumption rate (OCR) 
measurements and relative derived parameters after the addition of oligomycin [1 µM], 1 µM 
carbonylcyanide 4-(trifluoromethoxy)-phenylhydrazone (FCCP) [1 µM], and antimycin A [2 µM] + 
rotenone [2 µM] in MSCs cultured in low-glucose (LG), adipogenic (AD), and osteogenic (OS) media 
for (d) 7 and (e) 21 days. Data are derived from ≥45 acquired cells/condition from ≥3 independent 
experiments and are shown as the mean ± SD. ANOVA, * p < 0.1, ** p < 0.01, *** p < 0.001, **** p < 0.0001 
with respect to the LG condition at the same time point. 
The important decrease in mitochondrial mass and basal respiration after 21 days of 
osteogenesis suggests that the mitochondria formed at 7 days should be exhausted and destined for 
turnover. Mitophagy is a specialized type of autophagy specific for mitochondrial degradation 
through lysosomes [17], and to better characterize this interesting dynamic that occurs in 
mitochondria during osteogenesis, levels of specific mitochondrial proteins and markers of 
autophagy/mitophagy were followed during osteogenesis (Supplementary Figure S2). 
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We showed that a decrease in mitochondrial protein levels (Supplementary Figure S2a,b) is 
followed by an increase in autophagy, as shown by the marker LC3-II [18] and a decrease in PARKIN 
[19] (Supplementary Figure S2a). Moreover, colocalization of LC3-GFP dots and TOM20 confirmed 
that the late phase of osteogenesis is linked to the mitophagy process (Supplementary Figure S2c). 
3.2. Inhibition of Citrate Transporters Impairs Osteogenesis 
Mitochondrial metabolism plays a central role in cell energy metabolism, and the generation of 
mitochondrial metabolites represents a possible way by which mitochondria regulate stem cell fate. 
In fact, pivotal enzymes that regulate chromatin, and thus transcription, rely on mitochondrial 
metabolic intermediates [20–22]. Among the several metabolites of the TCA cycle, acetyl coenzyme 
A (acetyl-CoA) and αKG participate in the regulation of histone acetylation and methylation, 
respectively. Their common precursor is citrate, which is produced in the mitochondrial matrix and 
can enter the oxidative phase of the Krebs cycle or be transported from mitochondria to the cytosol 
where it can be reconverted in acetyl-CoA or αKG (through isocitrate as an intermediate). Citrate 
exits the mitochondria through mitochondrial citrate transport protein (CTP), a membrane-
embedded protein that catalyzes translocation of citrate across the mitochondrial inner membrane 
[23] (Figure 3a). 
 
Figure 3. Inhibition of the citrate transport system impaired osteogenic, but not adipogenic, 
differentiation. MSCs were cultured in low-glucose (LG), adipogenic (AD), and osteogenic (OS) 
media; where indicated, 1,2,3-benzenetricarboxylate (BTC) [5 mM] and CTP inhibitor (iCTP) [500 µM] 
were added to inhibit the transport of citrate produced in mitochondria to the cytosol. (a) Schematic 
representation of the acetyl-CoA transport system. In the mitochondrial matrix, acetyl-CoA is 
converted to citrate by citrate synthase. Citrate is then transported by the citrate transporter to the 
cytosol, where it is reconverted to acetyl-CoA by citrate lyase. (b,c) Cell survival assay to determine 
the concentration of BTC (b) and iCTP (c). Adipogenic differentiation was detected by (d) Oil Red O 
staining after 7 and 21 days of differentiation and by (e) analysis of relative mRNA levels of 
adipogenic markers (GLUT4, PPARγ, ADIPOQ, C/EBPα, and FABP4) after 21 days. ANOVA-test 
refers to the control (CTR) condition (adipogenic medium). Osteogenic differentiation was detected 
by (f) Alizarin Red staining after 7 and 21 days of differentiation and by (g) analysis of relative mRNA 
levels of osteogenic markers (RUNX2, RANKL, osteocalcin (OC), osteopontin (OPN), osterix (OSX), 
and alkaline phosphatase (ALP)) after 21 days. Data are derived from ≥3 independent experiments 
and are shown as the mean ± SD. ANOVA-test refers to the CTR condition (osteogenic medium). * p 
< 0.5, ** p < 0.01, *** p < 0.001. 
Cells 2020, 9, 1034 8 of 15 
 
CTP inhibitor (referred to herein as iCTP), the first purely competitive inhibitor to be discovered, 
inhibits of mitochondrial CTP and is more potent than 1,2,3-benzenetricarboxylate (BTC), the classic 
and defining inhibitor of mitochondrial CTP [24]. 
In the present study, MSCs were differentiated toward adipogenic and osteogenic lineages, and 
5 mM BTC or 500 µM iCTP, a dose that does not affect cell proliferation, was added as indicated 
(Figure 3b,c). BTC and iCTP treatment did not affect MSC adipogenesis, as shown by staining of lipid 
drop accumulation (Figure 3d and by the mRNA levels of adipogenic markers (GLUT4, PPARγ, 
ADIPOQ, C/EBPα, and FABP4) (Figure 3e). 
In contrast, BTC and especially iCTP strongly inhibited osteogenic differentiation. The calcium 
deposits detected by Alizarin Red staining were reduced in MSCs cultured in osteogenic medium 
plus BTC or iCTP compared to CTR conditions at both 7 and 21 days (Figure 3f). In addition, analysis 
of the mRNA profile of osteogenic markers (RUNX2, RANKL, osteocalcin, osteopontin, osterix, and 
alkaline phosphatase) confirmed that inhibition of mitochondrial citrate transport strongly impaired 
MSC osteogenic differentiation (Figure 3g). 
BTC also affected osteogenic-induced changes in mitochondrial morphology and 
mitochondrion-nucleus contact sites. As a result, MSCs treated with BTC resembled MSCs in the 
undifferentiated condition, confirming that mitochondrial changes are linked to the osteogenic 
differentiation (Figure 4a,b). 
 
Figure 4. Inhibition of the citrate transport system impaired mitochondrial behavior. MSCs were 
cultured in low-glucose (LG), adipogenic (AD), and osteogenic (OS) media; where indicated, BTC [5 
mM] and iCTP [500 µM] were added to inhibit the transport of citrate produced in mitochondria to 
the cytosol. (a) Representative images and (b) analysis of mitochondrial total volume and number 
detected by the anti-TOM20 Ab and the total volume and number of mitochondrion-nucleus contact 
sites. Magnification 40x. Scale bar 10 µm (in zoom panel, scale bar 5 µm). Data are derived from ≥45 
acquired cells/condition from ≥3 independent experiments and are shown as the mean ± SD. ANOVA-
test. * p < 0.5, ** p < 0.01, *** p < 0.001, **** p < 0.0001. 
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3.3. Citrate is Converted to αKG to Promote Osteogenesis 
Citrate in the cytosol can be converted to acetyl-coA or αKG (Figure 5a), two key metabolites 
able to regulate histone acetylation and methylation states. 
Several reviews have reported the effect of epigenetic modifications on MSCs multipotency and 
differentiation [25–27], among which H3K9ac and H3K9me3 are considered key epigenetic signatures 
indicative of transcriptional activation and inactivation, respectively [28]. These signatures interact 
with the osteogenic master transcriptional factor RUNX2 during osteogenesis [29]. 
We confirmed in our model that H3K9ac levels increased during osteogenesis (Supplementary 
Figure S3a) and that the osteogenesis defect caused by CTP inhibition resulted in H3K9ac levels that 
were comparable those of undifferentiated cells (low glucose). Without affecting cell growth, citrate 
conversion to acetyl-CoA by citrate lyase was inhibited by 1 mM BMS (Supplementary Figure S3c). 
Although BMS treatment was able to decrease the levels of H3K9ac (Supplementary Figure S3b), it 
also increased the osteogenic potential of MSCs (Figure 5b). This suggests that citrate accumulation 
due to citrate lyase inactivation promoted osteogenesis. To investigate whether αKG is necessary for 
osteogenesis, exogenous αKG (1 mM, Supplementary Figure S3d) was added to the differentiation 
medium, which promoted osteogenesis and partially rescued the phenotype due to CTP inhibition 
(Figure 5c). 
αKG is a substrate for the Jumonji-C (JmjC) domain-containing histone demethylase family of 
proteins that catalyze histone demethylation [30]. Because removal of H3K9me3 marks is required 
for osteogenesis [31], H3K9me3 levels were investigated. We confirmed that osteogenesis is linked to 
a reduction in H3K9me3 marks, whereas CTP inhibition resulted in levels comparable to those of 
undifferentiated cells; furthermore, αKG addition promoted demethylation (Figure 5e). 
Finally, to confirm that citrate should exit mitochondria and enter the nucleus to be converted 
into αKG and play a regulatory role in the methylation status of histones, we added αKG under 
conditions in which CTP was inhibited (αKG + BTC). Under this condition, osteogenic potential 
(Figure 5c) and methylation status (Figure 5e) were partially restored, as were mitochondrial 
morphology and contact sites (Figure 5d), confirming our hypothesis that citrate derived from 
mitochondria is essential to induce osteogenic differentiation. 
Cells 2020, 9, 1034 10 of 15 
 
 
Figure 5. Citrate from mitochondria increases the level of α-ketoglutarate to promote osteogenesis. 
(a) Citrate can be converted to acetyl-CoA by citrate lyase (inhibited by BMS) or to α-ketoglutarate 
(αKG), two metabolites that can mediate mitochondrion-nucleus communication. (b,c) Analysis of 
relative mRNA levels of osteogenic markers (RUNX2, RANKL, osteocalcin (OC), osteopontin (OPN), 
osterix (OSX), and alkaline phosphatase (ALP)) in MSCs cultured in low-glucose (LG) and osteogenic 
media (OS); where indicated, BMS [1 mM], BTC [5 mM], and αKG [1 mM] were added for 21 days. 
(d) Representative images and analysis of mitochondrial total volume and number detected by the 
anti-TOM20 Ab and the total volume and number of mitochondrion-nucleus contact sites in MSCs 
cultured in LG and osteogenic media (OS); where indicated, BTC [5 mM] and αKG [1 mM] were 
added for 21 days. (e) Representative images and quantification of H3K9me3 in MSCs cultured in LG 
and OS media; where indicated, BTC [5 mM] and αKG [1 mM] were added for 21 days. Magnification 
40x. Scale bar 10 µm (in zoom 5 µm). Data are derived from ≥45 acquired cells/condition from ≥3 
independent experiments and are shown as the mean ± SD. ANOVA-test. * p < 0.5, ** p < 0.01, *** p < 
0.001. 
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4. Discussion 
MSC differentiation has largely been investigated from a transcription factor point of view, 
whereas little is known concerning how metabolism might regulate this complex process. Due to the 
very distinct metabolic and energetic demands of differentiated cell types, stem cell differentiation 
requires variations in the number, structure, function, and intracellular distribution of mitochondria 
[32–34]. In particular, mitochondrial DNA copy number and intracellular ATP content as well as 
levels of protein subunits of the respiratory enzymes increase during osteogenic differentiation of 
MSCs [11,35]. 
In this study, we performed a detailed morphological analysis of the mitochondrial network by 
3D reconstruction in a single cell. We showed that during the early phase of adipogenic and 
osteogenic differentiation, mitochondria volume and number increased dramatically in agreement 
with the enhanced mitochondrial respiration (Figures 1 and 2), confirming previous evidence 
detected by the classical immunofluorescence technique [6,36]. The large number of mitochondria 
suggests increased mitochondrial biogenesis during both adipogenesis and osteogenesis. Our data 
are supported by a previous study [7], in which it was shown that the protein level of TOM20 was 
greatly increased during adipogenic differentiation, confirming the increase in mitochondrial mass. 
Interestingly, in the late phase of the differentiation process, adipogenic cells exhibited a conspicuous 
number of mitochondria, whereas osteogenic cells had few of these organelles (Figures 1 and 2). 
Recent studies have demonstrated a pivotal role of autophagy in the osteo-differentiation of hBMSCs 
[37–39], and mitophagy has been showed to be essential for the maintenance of hematopoietic stem 
cell [40]. Our data showed that autophagy and mitophagy levels are dynamically regulated during 
osteogenesis (Supplementary Figure S2), suggesting a possible crucial role of mitophagy in the MSCs 
differentiation process which should be deeply investigated in future studies. 
In addition to the general mitochondrial alterations commonly accepted, we deeply investigated 
the localization of mitochondria in relation to the nucleus, identifying sites of contact between the 
two organelles. It is generally accepted that mitochondria mainly accumulate around the nucleus in 
undifferentiated cells, whereas they are more uniformly distributed throughout the cytoplasm of 
differentiated cells [41,42]. Nonetheless, the number and volume of contact sites between the nucleus 
and mitochondria were found to increase following the early stage of the differentiation process 
(Figure 1). This let us to hypothesize a crucial communication between mitochondria and the nucleus, 
whereby contact sites create microdomains in which exchange of metabolites may be heightened to 
promote differentiation. 
Mitochondrial metabolism might be pivotal for stem cell fate regulation; indeed, metabolites 
generated in the TCA cycle can act as cofactors or substrates for chromatin-modifying enzymes. In 
fact, a growing body of evidence suggests that the metabolic profile of cells can influence cytoplasmic 
signaling and epigenetics [43–45]. Interestingly, several mitochondrial enzymes associated with the 
TCA cycle are essential for epigenetic remodeling and are transiently and partially localized to the 
nucleus during embryonic development [46]. 
Citrate plays a central role in highly proliferating undifferentiated stem cells and in their 
differentiation toward specific functional cell types [47]. In particular, we show that inhibition of the 
citrate transporter system dramatically affects osteogenesis, as opposed to adipogenesis (Figure 3). 
This finding highlights that mitochondrial citrate is fundamental for determining stem cell fate. 
Bone contains extremely high levels of citrate, which is an essential component of the apatite 
nanocrystal [48], and osteoblasts are the source of citrate that is incorporated into bone during bone 
formation [49]. Moreover, citrate functions as a chelating agent and binds physiologically relevant 
cations such as Ca2+, Zn2+, and Mg2+; thus, citrate constitutes the major store of calcium in bones [50]. 
For this reason, altered citrate metabolism may occur during the differentiation of mesenchymal stem 
cells to functional citrate-producing osteoblasts. 
In addition, citrate plays a role in the regulation of epigenetic markers. Although citrate can be 
converted to acetyl-coA or αKG (via isocitrate), we demonstrate that conversion of citrate to the latter 
rather than the former allows osteogenic differentiation (Figure 5). 
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αKG can enter the nucleus where it is used as a substrate by ten-eleven translocation (TET) 
proteins for DNA demethylation and by Jumonji C domain demethylases (JHDMs) for histone 
demethylation (linked to context-dependent gene silencing or activation) [51]. 
It has been reported that the maintenance of proper α-KG levels is fundamental in determining 
the identity and fate of embryonic stem cells (ESCs). Specifically, a high α-KG/succinate ratio 
promotes the activity of DNA and histone demethylases, and modifying this ratio is sufficient to 
regulate multiple chromatin modifications [52]. Lastly, we linked α-KG levels to H3K9me3, an 
epigenetic marker associated with the osteogenesis differentiation process. 
Taken together, our data suggest that during MSC differentiation, mitochondria assemble close 
to the nucleus to create microdomains to facilitate the exchange of metabolites from the mitochondrial 
matrix to the nucleus. Citrate exiting from mitochondria is converted to αKG, which promotes 
histone modification, leading to transcriptional activation of osteogenic-related genes. These findings 
highlight that mitochondrial metabolites play a key regulatory role in the differentiation process, 
which should be deeply investigated in the future and may reveal novel therapeutic strategies in the 
field of regenerative medicine. 
Supplementary Materials: Supplementary Materials is available online at www.mdpi.com/2073-
4409/9/4/1034/s1. Figure S1: Detection of cell surface markers by flow cytometry, Figure S2: Mitophagy activation 
in the late stage of osteogenesis, Figure S3: Modulation of citrate transport system. 
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